RAPT Therapeutics, Inc. (RAPT)

RAPT Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	47.48	38.95	24.03	24.92	77.38
Short-Term Investments	111.38	210.12	165.63	86.59	0
Cash & Cash Equivalents	158.86	249.07	189.65	111.51	77.38
Cash Growth	-36.22%	31.33%	70.08%	44.10%	21.29%
Other Current Assets	2.92	3.63	3.32	4.09	3.12
Total Current Assets	161.78	252.69	192.97	115.6	80.51
Property, Plant & Equipment	7.68	9.48	2.74	2.98	3.71
Other Long-Term Assets	3.87	4.04	2.92	0.39	0.39
Total Long-Term Assets	11.55	13.52	5.66	3.37	4.1
Total Assets	173.33	266.21	198.64	118.97	84.6
Accounts Payable	5.18	3.37	2	2.38	1.14
Deferred Revenue	0	0	1.53	4.96	4
Current Debt	2.45	2.17	0	0	0
Other Current Liabilities	14.21	8.69	6.07	4.4	4.11
Total Current Liabilities	21.84	14.22	9.6	11.74	9.26
Long-Term Debt	4.46	6.82	0	0	0
Other Long-Term Liabilities	0	0	2.66	3.05	2.23
Total Long-Term Liabilities	4.46	6.82	2.66	3.05	2.23
Total Liabilities	26.29	21.04	12.26	14.79	11.48
Total Debt	6.91	8.99	0	0	0
Debt Growth	-23.18%	-	-	-	-
Retained Earnings	-484.68	-367.88	-284.05	-214.84	-161.95
Comprehensive Income	0.1	-0.03	-0.21	-0.18	0.02
Shareholders' Equity	147.04	245.17	186.38	104.18	73.12
Net Cash / Debt	151.96	240.08	189.65	111.51	77.38
Net Cash / Debt Growth	-36.71%	26.59%	70.08%	44.10%	21.29%
Net Cash Per Share	3.96	7.38	6.92	4.62	17.80
Working Capital	139.95	238.47	183.38	103.86	71.25
Book Value Per Share	3.83	7.53	6.80	4.32	16.82

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).